Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

d special and acquisition-related charges

(f) Included in cumulative effect in change in accounting principle, net

SCHERING-PLOUGH CORPORATION

Report for the period ended December 31 (unaudited):

GAAP Net Sales by Key Product

(Dollars in millions) Fourth Quarter Full Year

2007 2006 % 2007 2006 %

GLOBAL

PHARMACEUTICALS a/ $2,963 $2,211 34% $10,173 $8,561 19%

REMICADE 455 337 35% 1,648 1,240 33%

NASONEX 271 253 7% 1,092 944 16%

PEGINTRON 239 208 15% 911 837 9%

TEMODAR 234 189 23% 861 703 22%

CLARINEX /

AERIUS 174 164 6% 799 722 11%

CLARITIN RX 93 78 19% 391 356 10%

AVELOX 115 103 12% 384 304 26%

INTEGRILIN 91 85 7% 332 329 1%

REBETOL 71 75 (6%) 277 311 (11%)

CAELYX 66 49 33% 257 206 25%

INTRON A 57 57 - 233 237 (2%)

SUBUTEX /

SUBOXONE 57 51 11% 220 203 8%

PROVENTIL /

ALBUTEROL CFC 41 55 (25%) 207 203 2%

ASMANEX 41 36 16% 162 103 57%

ELOCON 37 33 10% 156 141 11%

FORADIL 25 28 (11%) 102 94 8%

NOXAFIL 29 10 N/M 89 19 N/M

FOLLISTIM c/ 57 - N/M 57 - N/M

NUVARING c/ 45 - N/M 45 - N/M

<
'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... SAN DIEGO and BETHESDA, ... announced today that they are joining together with ... (NIH) to help scientists develop more reliable tools ... on a faster timeline. Organovo is collaborating with ... and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... Jan. 14, 2014  RXi Pharmaceuticals Corporation ... discovering, developing and commercializing innovative therapies addressing ... today announced that it received the Notice ... and Trademark Office on its unique self-delivering ... fibrosis. The patent covers the use of ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ... staff,” said Dr. Andrew Brown, SPIE Senior Director for ...
(Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ... called WebBytez . WebBytez is a patent-pending way ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... becoming increasingly flatter - some have even become almost as ... dimensions, much to the delight of home cinema fans. Cellphones ... All of these developments owe their thanks to miniature light-emitting ... multitude of devices. However, LED technology does have a ...
... 16 Accuray Incorporated (Nasdaq: ARAY ), a global leader in ... at the Wells Fargo Securities Healthcare Conference in Boston on ... PT . , , , ... the presentation will be available online from the investor relations page of the ...
... Trans World Alloys (TWA), one of the country,s premier titanium sheet ... joined the company, as its new Chief Operating Officer. ACCORDING TO SANDY SHADROW, ... the metal business in a variety of areas." , ... Ed has attended the University of Baltimore , the ...
Cached Biology Technology:World of lights in the microcosmos 2Accuray Incorporated to Speak at Wells Fargo Securities Healthcare Conference 2Ed Brennan - New C.O.O. of Trans World Alloys 2
(Date:4/16/2014)... and soil processes are to blame for significant baseline ... a study published recently in the Journal of ... samples from all corners of Ohio showed that every ... of concern recommended by the U.S. Environmental Protection Agency. ... authors, who note that regulatory levels typically are set ...
(Date:4/16/2014)... Leo Heim and their colleagues at the University of ... of generating hydrogen using water and formaldehyde. The generation ... it comes to fuel cell technologies. The results of ... water and formaldehyde", have recently been published in the ... the new approach can be used to recycle industrial ...
(Date:4/15/2014)... Calif. UC Irvine neurobiologists have found that genetically ... into the brains of mice with the symptoms and ... in the journal Stem Cells Research and Therapy ... in two different mouse models. , Alzheimer,s disease, ... associated with accumulation of the protein amyloid-beta in the ...
Breaking Biology News(10 mins):Significant baseline levels of arsenic found in Ohio soils are due to natural processes 2Significant baseline levels of arsenic found in Ohio soils are due to natural processes 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 4UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2
... 2010) When researchers tested three different labeling agents ... effect the labeling agents had on stem cell phenotype, ... stem cell proliferation depending on the type of contrast ... and Spain tested USPIO (ultra small superparamagnetic iron oxide) ...
... voracious predatory crabs due to global warming could threaten ... published findings. "King crabs are ecologically important ... fisheries," said Dr Sven Thatje, an evolutionary ecologist at ... Science (SOES), which is based at the National Oceanography ...
... to spot prey, vision keeps many animals, including humans, alive. ... is it easier for us to spot movement of small ... things? The complexity of the neural network that supports vision ... and support from the National Science Foundation, Claire Wyart in ...
Cached Biology News:MRI contrast agents change stem cell proliferation 2King crab distributions limited by temperature in the Southern Ocean 2The zebrafish's neural circuit prevents it from biting off more than it can chew 2
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Request Info...
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: